Search Results - Subhashis Banerjee
-
1
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis:...
Published 2024Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso -
2
Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO ‐1, PSO ‐4, and LTE trials
Published 2025Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso -
3
Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient‐reported outcomes in the POETYK PSO‐4 study
Published 2024Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso -
4
Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials
Published 2025Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso